The neuronal ceroid lipofuscinoses are a class of inherited neurodegenerative diseases characterized by the accumulation of autofluorescent storage material. The most common neuronal ceroid lipofuscinosis has juvenile onset with rapid onset blindness and progressive degeneration of cognitive processes. The juvenile form is caused by mutations in the CLN3 gene, which encodes the protein CLN3. While mouse models of Cln3 deficiency show mild disease phenotypes, it is apparent from patient tissue-and cell-based studies that its loss impacts many cellular processes. Using Cln3 deficient mice, we previously described defects in mouse brain endothelial cells and blood-brain barrier (BBB) permeability. Here we expand on this to other components of the BBB and show that Cln3 deficient mice have increased astrocyte endfeet area. Interestingly, this phenotype is corrected by treatment with a commonly used GAP junction inhibitor, carbenoxolone (CBX). In addition to its action on GAP junctions, CBX has also been proposed to alter lipid microdomains. In this work, we show that CBX modifies lipid microdomains and corrects membrane fluidity alterations in Cln3 deficient endothelial cells, which in turn improves defects in endocytosis, caveolin-1 distribution at the plasma membrane, and Cdc42 activity. In further work using the NIH Library of Integrated Network-based Cellular Signatures (LINCS), we discovered other small molecules whose impact was similar to CBX in that they improved Cln3-deficient cell phenotypes. Moreover, Cln3 deficient mice treated orally with CBX exhibited recovery of impaired BBB responses and reduced autofluorescence. CBX and the compounds identified by LINCS, many of which have been used in humans or approved for other
Introduction
The neuronal ceroid lipofuscinoses (NCLs) are progressive neurodegenerative diseases characterized by the accumulation of autofluorescent material in multiple cell types. The most common NCL has a juvenile onset and is commonly caused by mutations in CLN3 (referred to as CLN3 deficiency) (Williams and Mole, 2012) . CLN3 deficiency generally manifests with early visual deficits followed several years later by seizures with mental and physical decline (Phillips et al., 2005) . To date, only palliative care is available for this invariably fatal disease.
The CLN3 gene encodes the protein CLN3 (also known as battenin), which is a 438 amino acid hydrophobic, multi-pass transmembrane protein of unresolved function (Cotman and Staropoli, 2012; Phillips et al., 2005) . Work in model systems over the last two decades suggest that CLN3 impacts multiple cellular functions including lysosomal pH (Golabek et al., 2000; Holopainen et al., 2001; Pearce et al., 1999; Pearce and Sherman, 1998) , vesicular trafficking (Cao et al., 2006; Codlin and Mole, 2009; Fossale et al., 2004; Kama et al., 2011; Metcalf et al., 2008) , palmitoyl desaturase activity (Narayan et al., 2006) , endocytosis (Codlin et al., 2008; Fossale et al., 2004; Luiro et al., 2001; Luiro et al., 2004; Schultz et al., 2014; Tecedor et al., 2013; Vidal-Donet et al., 2013) , and membrane microdomain formation or stability (Tecedor et al., 2013) .
Using a Cln3 reporter mouse we previously showed that Cln3 is highly expressed in brain vasculature endothelial cells (Eliason et al., 2007) . Brain endothelial cells are a component of the blood-brain barrier (BBB) and are vital for the maintenance of
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A C C E P T E D M A N U S C R I P T neuronal health and CNS function. In some neurodegenerative diseases, such as Alzheimer's disease, endothelial cell dysfunction (Sagare et al., 2013) at the BBB is a critical element in disease pathogenesis. Intriguingly, CLN3 disease patients and mouse models display autoantibodies against CNS antigens in peripheral blood. Concurrently, high levels of storage material accumulate in endothelial cells (Lamb et al., 2006; Lim et al., 2007) . Additionally, Cln3-null mice have abnormal BBB responses to hypotonic stress in vivo (Tecedor et al., 2013) . Whether other components of the BBB, for example astrocytes whose endfeet are a constituent of the BBB, are affected in CLN3 deficiency is not known.
Here, we report that Cln3-null mice have increased astrocyte endfeet area in the BBB. Increased astrocyte endfeet size could reflect defects in astrocyte communication, which occurs at GAP junctions. Indeed prior work in slice culture models have shown excessive astrocytic GAP junction connectivity (Burkovetskaya et al., 2014) .
Interestingly, we found that oral treatment of Cln3
-/-mice with the GAP junction inhibitor Carbenoxolone (CBX) significantly corrects astrocyte endfeet area. CBX exerts its impact on GAP junction/hemichannel activity upon intercalation into the plasma membrane, which likely alters membrane microfluidity (Davidson and Baumgarten, 1988; Goldberg et al., 1996; Tovar et al., 2009) . Interestingly, we previously described altered plasma membrane fluidity in endothelial cells derived from Cln3 -/-mice (Tecedor et al., 2013) . A C C E P T E D M A N U S C R I P T
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Materials and Methods
Mice
All animal experiments were approved by the University of Iowa animal care and use committee and conducted in accordance with institutional and federal guidelines. Here we used (WT), Cln3 lacZ/+ (Cln3 -/+ ), and Cln3 lacZ/lacZ (Cln3 -/-) mice (Eliason et al., 2007) backcrossed to the C57BL/6J background. Mixes of male and female mice were used for experiments.
MBEC cell lines
Due to the low yield of primary MBECs, we used previously described immortalized MBEC from Cln3 -/-mice (Tecedor et al., 2013) . Cln3 expression was stably restored in
Cln3
-/-MBEC using a lentivirus vector as described previously (Tecedor et al., 2013) (Schultz et al., 2014; Tecedor et al., 2013) . Immortalized
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GAP junction connectivity
MBECs were incubated with 5 µM calcein-AM (Molecular probes) for 30 minutes at 37°C in the dark, then rinsed briefly with cold cell culture media. Whole cells were photobleached as described above in the Membrane fluidity section. Post-bleached images were captured every 5s. Neighboring cells were used as controls for sequential bleaching due to the imaging process. FRAP was quantified as described previously (Kenworthy, 2007) . Results from three independent experiments were analyzed together (n= 76, 42, 52, 52 for Cln3
Two-way ANOVA resulted with significant interaction. Data was analyzed for each time point by one-way ANOVA followed by Tukey's post-hoc analysis.
Cholesterol quantification
Detergent-free carbonate extraction and discontinuous sucrose density centrifugation was used to enrich plasma membrane and separate lipid microdomain fractions as before (Tecedor et al., 2013) . Cholesterol was quantified by amplex red assay (Life Technologies). Briefly, cell fractions were diluted in reaction buffer and incubated with the amplex red reagent per the manufactures instructions. Cholesterol intensity was quantified for each membrane fraction with a monochrome microplate reader Safire2
(Tecan Group Ltd. Mannedorf, Switzerland). Results were normalized to total amount of quantified cholesterol per the manufacturer's instructions.
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Cdc42-GTP analysis
The Cdc42 G-Lisa ® from Cytoskeleton Inc. was utilized for measurement of Cdc42-GTP levels. Briefly, 0.8 mg/ml of snap frozen lysate was incubated in the ELISA plate and the manufactures instructions were followed for detection and analysis as previously described (Schultz et al., 2014) . Data were normalized to the protein standard and significance was tested by one-way ANOVA with Tukey post-hoc analysis.
Fluid-phase endocytosis
Subconfluent cells were incubated with 0.5 mg/ml Alexa 488 10,000 MW dextran (Invitrogen) for 20 minutes. Then cells were briefly washed 3X with 37° PBS to remove unbound dextran and immediately fixed with 4% PFA at 37°C. Membrane impermeable 200 mM Red-40 was added to quench extra cellular dextran signal allowing quantification of only internalized dextran (Schultz et al., 2014) . Cells were immediately imaged on an Olympus IX81 microscope and fluorescent intensity was calculated by
ImageJ. Significance was determined by a one-way ANOVA with Tukey post-hoc ( Fig.   5C ) analysis or one-way ANOVA with Holm-Sidak's multiple comparisons post-hoc ( Fig.   6B ) comparing each treatment with the CLN3 -/-MBEC + vehicle group.
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Immunofluorescence
Sub-confluent MBECs were briefly washed and fixed in 4% PFA, permeabilized with 0.01% Trition-X-100, washed three times with PBS, and blocked for 1 hour with 2% goat serum. Cells were incubated overnight with Cav-1 antibody (1:200) Abcam, washed three times, and incubated with goat anti-rabbit Alexa 488 secondary for 45 minutes.
After mounting with Vectashield, cells were imaged on a Zeiss 710 confocal microscope.
Protein analysis
Three confluent 160-mm-diameter dishes of MBECs were harvested and plasma membranes were isolated as previously described (Yao et al., 2009 
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A C C E P T E D M A N U S C R I P T quantified by densitometry using Image Lab 5.1 (Bio-Rad) software. Plasma membrane connexin43 levels were normalized to plasma membrane transferrin receptor. This value was normalized to total ß-catenin as a housekeeping reference protein.
BBB hypotonic treatment
Mice were anesthetized and perfused with a Gilson minipulse 3 pump (set to a speed of 2 
Astrocyte endfeet quantification
3 mice per group were perfused with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer using a Gilson minipulse 3 at ~1.3 ml/min flow ratio for maintaining BBB integrity.
Motor cortex samples of 1mm 2 were collected, and 50 µm vibrotome sections were obtained. Samples were then postfixed in 1% osmium tetroxide for 1 hr., stained with
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Ultrathin 70 nm sections were cut on a Leica UC6 ultramicrotome (Leica Microsystems) and 12-23 cortical capillaries per animal analyzed with a 1230 JEOL-JEM transmission EM (Jeol USA) or a Zeiss Libra 120 transmission EM. Microvasculature was recognized by detecting the basal lamina which is localized between endothelial cells and astrocytic endfeet. Only long processes surrounding the basal lamina were measured to exclude neuronal terminals. The area surrounded by astrocytic endfeet plasma membrane was measured using ImageJ software (NIH). Endfeet data did not follow a normal distribution so it was normalized by lognormal transformation. Statistical significance of the normalized data was tested by two-tailed t-test.
Autofluorescence
Brains were collected as explained above in the BBB hypotonic treatment method. From each brain, 20 X images were taken from four different sections of medial cortex.
Autofluorescence images were collected in the red channel and intensity calculated using ImageJ. Significance was calculated by a one-way ANOVA with Tukey post-hoc analysis.
Drug treatment
Carbenoxolone disodium salt ( 
LINCS database analyses
Cln3
-/-MBE cells were treated with 3 µM CBX or no-treatment for 18 hrs., following which RNA was harvested from 6 wells per condition using the mirVana TM total RNA isolation kit procedure. Total RNA was tested for quality on an Agilent Model 2100
Bioanalyzer (Agilent Technologies), and gene expression profiles were generated using the MouseRef-8 V2 BeadChip Kit (Illumina). Every reference signature in the database is compared with the query signatures and given a score termed the "connectivity score" based on the extent of similarity between the two. Scores range from +1 meaning higher similarity, to 0 meaning no similarity, to -1 meaning opposite similarity. We removed all non-compounds and negative connectivity scores, and sorted the remaining compounds by connectivity score alone.
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We prioritized the top 70 compounds with the highest connectivity score for further analysis.
Experimental design and statistical analysis
Data are presented as mean ± s.e.m. with p values, and sample size (n). Prism v6 (GraphPad Software) was used for statistical analyses. Comparisons between different datasets were made depending on data distribution tested by the D'Agostino normality test. Parametric tests were used for normally distributed data (two-tailed t-test for comparing two groups and ANOVA for comparing three or more groups). A two-way
ANOVA was used to determine significance in experiments with multiple time points and groups. When a significant interaction was found between factors by two-way ANOVA, one-way ANOVA were used to determine significance between experimental groups.
When the normality assumption was violated, nonparametric tests were performed (Mann-Whitney test for two groups and Kruskal-Wallis for three or more groups) unless the n was high enough to allow the transformation of the data to a normal distribution using lognormal function. Differences were considered statistically significant at p<0.05.
Different levels of significance between groups were denoted as * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001
Results
An astrocyte endfeet phenotype in CLN3-null mice is corrected by CBX
At the BBB, astrocytes and brain endothelial cells are juxtaposed at astrocyte endfeet, which together serve to regulate BBB maintenance and function (Abbott et al., 2006 ). As we previously described structural alterations in mouse brain endothelia in vivo (Tecedor et al., 2013) , we next tested cerebral sections for structural changes in MBECs from null or WT mice, respectively (Schultz et al., 2014; Tecedor et al., 2013) .
To study the impact of Cln3 deficiency on GAP junction connectivity, MBEC monolayer cultures were incubated with calcein-AM, which moves between cells using GAP junctions and the cell-cell transfer rate quantified using whole cell fluorescence recovery after photobleaching (FRAP). For FRAP, the fluorescent calcein-AM in one cell is photobleached and then sequential images taken to determine the rate by which the dye enters the photobleached cell from neighboring cells. FRAP analysis revealed that MBECs ( Fig. 2B ; Kruskal-Wallis, p=0.1085). This indicates that increased GAP junction activity is not caused by more Cx43 protein and suggests another mechanism for increased calcium-AM flow.
Although CBX is commonly used as a GAP junction inhibitor, data also support the notion that it directly modifies cell membranes. Administration of CBX to purified lysosomes stabilizes membranes (Porta et al., 1986; Symons et al., 1978) , and incubation of enveloped viral particles with CBX reduces adsorption (Dargan and Subak-Sharpe, 1986 ) and viral release (Dargan and Subak-Sharpe, 1986) . As GAP junctions are associated with cholesterol-rich domains (Schubert et al., 2002) and regulated by membrane fluidity (Bastiaanse et al., 1993) , we tested if CBX influences lipid microdomain dynamics by evaluating GM1 ganglioside movement in the plasma membrane. GM1 gangliosides were labeled in living MBECs with Alexa-488-cholera toxin subunit B (A488-CTB) and a high intensity laser was used to photobleach a A488-CTB-positive region of the plasma membrane. Sequential images were captured to assess the rate of A488-CTB movement into the photobleached area. Consistent with our previous report (Tecedor et al., 2013) , Cln3 -/-MBECs displayed significantly faster recovery compared to Cln3 R cells, indicating enhanced membrane fluidity (Fig. 3A ).
When MBECs were tested after 2 hours of CBX treatment, fluorescence recovery in
Cln3
-/-cells was normalized (one-way ANOVA F(3,108)=18.10, p<0.0001) (Fig. 3A) .
To determine if CBX corrects the previously described abnormal distribution of microdomain lipids (Tecedor et al., 2013) , plasma membranes were isolated and
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Cln3
-/-MBECs such that cholesterol concentration peaked in fraction 2. (Fig. 3B, Fig.   S1 ).
Cumulatively, these data support a model where CBX is a novel modifier of lipid microdomains. Interestingly, CBX did not significantly alter microdomain dynamics or the partitioning of cholesterol in Cln3 R MBECs.
CBX restores Cav-1 plasma membrane distribution
Since CBX corrected membrane fluidity dynamics in Cln3 -/-MBECs, we subsequently investigated if CBX corrects caveolar defects. Caveolae are flask-shaped invaginations that form within distinct cholesterol/sphingolipid-enriched lipid microdomains on the plasma membrane. Caveolae are common in BBB endothelia, where they serve as signaling platforms, mediate endocytosis, and transcytosis. The primary structural protein of caveolae is caveolin-1 (Cav-1). Cav-1 inserts into membranes at the ER and traffics through the Golgi where high-order oligomerization drives transport to the plasma membrane (Chadda et al., 2007) . We previously found enhanced microdomain fluidity in Cln3 -/-MBECs and modified Cav-1 distribution as assessed by fractionation and immunofluorescence of the plasma membrane. Altered
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plasma membrane Cav-1 distribution causes reduced caveolae formation in vitro and in vivo (Tecedor et al., 2013) . As shown in Fig. 4 , CBX treatment of Cln3 -/-MBECs increased Cav-1 immunosignal at the plasma membrane, evaluated by immunocytochemistry (Fig. 4A) ; western blot analysis of membrane enriched fractions showed no differences in Cav-1 protein levels (one-way ANOVA, F(3,20)=0.3744, p=0.7724; Fig. 4B ) implying that trafficking not protein expression levels were impacted by CBX treatment. The corrective effect of CBX on these phenotypes is similar to our prior work where addition of exogenous lipids recovered Cav-1 plasma membrane localization (Tecedor et al., 2013) . Cumulatively, the data support that CBX is acting to modify membranes in MBECs.
CBX corrects Cdc42-dependent defects in Cln3 -/-MBECs
In addition to caveolar endocytosis, Cln3 -/-MBECs have decreased levels of fluidphase endocytosis (FPE) and increased GTP-loaded Cdc42 (Schultz et al., 2014) .
Cdc42 is a small GTPase that cycles between GTP-bound (active, effector-binding) and GDP-bound (inactive) states (Chadda et al., 2007; Nevins and Thurmond, 2006; Rojas et al., 2001 ). Cdc42 GTP-to-GDP cycling is required for fluid-phase endocytosis and cell migration, both of which are reduced in Cln3 -/-cells (Schultz et al., 2014) . This suggests that inefficient cycling of Cdc42 to the "off" state underlies multiple actin-related defects in MBEC, and suggests further that drugs able to promote cycling may have beneficial effects.
We incubated subconfluent MBECs with CBX and quantified Cdc42-GTP levels. As expected, in vehicle-treated cells, active Cdc42 levels were significantly higher in Cln3 Figure 5A ). In Cln3 R MBECs, CBX did not significantly alter Cdc42-GTP levels (Fig. 5A) , likely due to the already low baseline levels of Cdc42-GTP as shown previously (Schultz et al., 2014) . In contrast, CBX treatment significantly reduced the levels of Cdc42-GTP in Cln3 -/-MBECs ( Figure 5A ; ANOVA, F(3, 16)=9.947, p=0.0006).
Correction of Cdc42-GTP suggested that CBX may mitigate the downstream actin-dependent cell migration and fluid-phase endocytosis defects previously found in
Cln3
-/-cells (Schultz et al., 2014) . To test for correction of cell migration, a scratch wound was made in confluent monolayers of Cln3 R and Cln3 -/-MBECs. Cells were subsequently treated with vehicle or CBX overnight and imaged using live cell microscopy to assess cell migration over time, and the percentage of wound remaining at each time point calculated. As in our former report (Schultz et al., 2014) (Fig. 5B,   Fig. S2 ). Thus, CBX is effective at correcting the cell migration defect in Cln3 -/-MBECs.
In addition to the role of Cdc42 on cell migration, Cdc42 is a key regulator of fluid-phase endocytosis (Kumari and Mayor, 2008; Schultz et al., 2014) . Impaired fluid phase endocytosis has been reported for Cln3 mutant yeast, Cln3 -/-mouse brain endothelial cells, Cln3 -/-neuronal cells, and in fibroblasts harvested from patients with CLN3 deficiency (Codlin et al., 2008; Fossale et al., 2004; Luiro et al., 2004; Schultz et al., 2014; Vidal-Donet et al., 2013) . We therefore measured fluid-phase endocytosis by uptake of fluorescently labeled dextran in cells treated with CBX or vehicle. CBX Cdc42 regulation and the associated actin-dependent functions. To our knowledge, the impact of CBX on Cdc42 activity and Cdc42-dependent cellular processes has not been previously tested.
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LINCS compounds correct fluid-phase and caveolar defects in Cln3 -/-MBECs
We next employed a transcriptome-based discovery approach to identify drugs that may mimic the effects of CBX (Fig. 6A) . We generated gene expression signatures (Lamb et al., 2006) to identify small molecules that induced gene expression profiles similar to that induced by CBX. We also analyzed the effect of enoxolone, a metabolite of CBX (Iveson et al., 1971) . Of hits, we focused on hydrophobic, neutral molecules that could impact membrane fluidity, and screened these for their ability to correct FITC-dextran uptake. The top six molecules (Prd, α-KC, K8, K9, K4, and K2) significantly increased fluid-phase endocytosis in Cln3 -/-MBEC ( Fig. 6B ; one-way ANOVA, F(9,128)=15.58, p<0.0001), similar to CBX.
For caveolar endocytosis to occur, plasma membrane Cav-1 is phosphorylated.
In Cln3 -/-MBECs, the altered distribution of Cav-1 at the plasma membrane coincides with a decrease of caveolae number and reduction in phosphorylated Cav-1 (P-cav-1) (Tecedor et al., 2013) . We therefore tested if plasma membrane-resident phospho-cav-
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1 was corrected by the LINCS hit compounds. Interestingly, we found that P-cav1 levels significantly recovered after treatment with CBX, its metabolite enoxolone, α-KC, K8, or K9 ( Fig. 6C ; Mann-Whitney test). Treatment with Prd, K4, or K2 did not reach statistical significance but showed a positive trend (Fig. 6C) .
In vivo CBX treatment increases BBB responses and reduces autofluorescence
Brain endothelial cells are vital for maintaining the integrity of the BBB.
Interestingly, injecting hypotonic solutions into blood induces an osmotic gradient across the BBB endothelium (Tecedor et al., 2013) . In wildtype mice, this osmotic gradient triggers endothelial cell swelling followed by over-shrinkage, allowing small molecule access to the underlying neuropil (Kozler and Pokorny, 2003; Reid and O'Neil, 2000; Tecedor et al., 2013) . The in vivo response to hypotonic shock is defective in Cln3 -/-mice, as demonstrated by impaired passage of small molecule reporters into the brain (Tecedor et al., 2013 ). Here we tested if short-term oral dosing of CBX corrects this defect in aged (8-month old) Cln3-null mice. For this, Cln3 -/-and Cln3 +/+ mice were gavaged daily with low-dose CBX or vehicle for two weeks, after which they were subjected to hypotonic challenge along with a dye that, unless the vasculature is compromised (e.g., by hypotonic challenge), remains restricted to the vascular lumen. As before, we used Hoechst dye penetration as a readout for the leakiness of the vasculature (Tecedor et al., 2013) . For optimal detection of dye leaking into brain parenchyma, our procedure was modified to include sequential delivery of i) labeled Alexa488-conjugated wheat germ agglutinin (WGA) to label the luminal surfaces of the vasculature, ii) isotonic (control) or hypotonic solution containing
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Hoechst dye, and iii) fixative (Fig. 7A) . As expected, Cln3 +/+ mice treated with isotonic solution do not show extravasation of dye into the brain parenchyma but instead, the dye remains confined to the vessel lumen (Fig. 7A) . In vehicle-gavaged mice, hypotonic-induced Hoechst penetration was evident in Cln3 +/+ mice, but minimal in
Cln3
-/-mice (Fig. 7B ), in line with our previous report (Tecedor et al., 2013) . In contrast, CBX-treated Cln3 -/-mice had substantially increased Hoechst signal in the parenchymal tissue, with the amount of Hoechst dye penetration similar to Cln3 +/+ mice treated with CBX (Fig. 7B ). These data indicate that CBX normalizes the impaired BBB response of Cln3 -/-mice.
In addition to the various BBB defects, JNCL patients and Cln3 mutant mouse models display progressive accumulation of autofluorescence in multiple cell types (Cotman et al., 2002; Mole et al., 2005; Stein et al., 2010) . Due to the close proximity of the BBB to brain neuropil, we next investigated if CBX alters the accumulation of parenchymal autofluorescence. For this study, aged (8 month old) Cln3 +/+ and Cln3 -/-mice were gavaged with CBX or vehicle for two weeks and cortical autofluorescence quantified. As expected, vehicle treated Cln3 -/-mice showed extensive autofluorescence levels compared to wildtype mice. Of note, there was significant reduction of autofluorescence (Kruskal-Wallis, p=0.0234) in CBX-treated Cln3 -/-mice relative to those that received vehicle-treatment (Fig. 7C ).
Discussion
We show that Cln3 -/-mice have increased astrocytic endfeet area (Fig. 1A) .
Interestingly, enlarged astrocytic endfeet were lacking the notable organelles or
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Post stroke, astrocyte endfeet swelling is hypothesized to prevent serum protein entry into the brain (Xiang et al., 2016) . Enlarged astrocyte endfeet in Cln3 -/-deficient mice may explain the decreased permeability of the Hoechst dye into the brain during hypotonic stress (Fig. 7) . Interestingly, this phenotype improved with CBX treatment (Fig. 1B) .
Additionally, we found increased GAP junction activity in MBECs which was corrected with CBX ( Fig. 2) . Although CBX is a GAP junction inhibitor, our data support that it also modifies lipid microdomains, affecting fluidity and correcting the regulation and function of caveolar and fluid-phase endocytosis (Figs. 2-5 ). CBX is hypothesized to alter hemi channel opening or synaptic transmission by directly intercalating into the plasma membrane (Davidson and Baumgarten, 1988; Goldberg et al., 1996; Tovar et al., 2009) . This is consistent with previous reports where CBX was shown to have membrane stabilizing effects, which are dependent on lipid concentration (Symons and Parke, 1980) . Interestingly, CBX application to wild type cells had little effect, suggesting that the microdomain modifying effect of CBX may be context dependent.
Although we demonstrate an effect on membrane dynamics, the exact mechanism of how CBX modifies lipid microdomains or corrects the in vitro and in vivo phenotypes tested here is not known. CBX can modify lysosomal permeability (Symons and Parke, 1980) , reduce fatty acid induced reactive oxygen species, inhibit sterol regulatory element binding protein-1c (Rhee et al., 2012) , alter calcium signaling (Liu et al., 2010) , inhibit 11-beta hydroxysteroid dehydrogenase (Monder et al., 1989) , and increase heat
A C C E P T E D M A N U S C R I P T shock protein expression (Nagayama et al., 2001) . One could argue that modulation of one or more of these pathways could influence the cellular phenotypes investigated in this study. However, we found that CBX restores most in vitro cell phenotypes quickly (within one to two hours), and speculate that it has a direct influence on cell membranes, creating conformational shifts and altered functions of membraneassociated proteins.
We also found other small molecules that behaved similarly to CBX (Fig. 6 ). These were identified using an unbiased genomics-based drug-discovery strategy (NIH Library of Integrated Network-based Cellular Signatures, LINCS). Compound screening allowed us to prioritize six small molecules that rescued membrane dynamics to levels comparable to CBX. Interestingly, all six small drugs are uncharged and hydrophobic.
These drugs have the potential to intercalate into membranes and produce physicochemical effects on lipid bilayers (Royer et al 2009 , Ragot et al. 2013 , Heier et al 2013 . These drugs were effective at correcting fluid-phase endocytosis and Cavphosphorylation in Cln3 -/-cells, and support the hypothesis that correcting membrane deficiencies in JNCL may be therapeutically beneficial (Fig. 6 ).
CXB has a steroid-like structure and a blood half-life of 13-26 hours (Baron et al., 1978; Davidson and Baumgarten, 1988; Hayes et al., 1977) . Recently a BBBpermeable derivative of CBX (Leshchenko et al., 2006) , INI-0602, was used to alleviate excessive hemichannel activity associated with Cln3 -/-mouse glial cells, and this drug showed positive effects in Cln3 -/-mouse slice culture models (Burkovetskaya et al., 2014) . Using a novel BBB permeability assay, we found that CBX treatment restored
A C C E P T E D M A N U S C R I P T the BBB response to hypotonic shock. Moreover, two-weeks of CBX treatment resolved autofluorescence in Cln3 -/-mouse brain (Fig. 7) .
Rodent gut microflora hydrolyzes CBX into sulfate conjugates of enoxolone (Iveson et al., 1971) , which enters the blood stream with subsequent presence in the brain and CSF (Tabuchi et al., 2012) . Interestingly, both CBX, and enoxolone corrected the in vitro phenotypes. As CBX does not cross the BBB (Leshchenko et al., 2006; Takeuchi et al., 2011) , the metabolite enoxolone may be responsible for the reduced autofluorescent storage either by improving the astrocytic phenotype, the endothelial phenotype, or both. Studies show that amyloid-β accumulation in Alzheimer's disease brain is due in part to faulty clearance by brain endothelial cells (Sagare et al., 2013) , and recent work in the JNCL field shows that, in vitro, normalizing astrocytes can improve neuronal phenotypes (Parviainen et al., 2017) . Regardless of the exact cell type and mechanism of action, CBX and the LINCS compounds provide promising therapeutic avenues for treatment of CLN3 deficiency disease.
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